Healthcare stocks are breaking out on fundamental wins — accumulate Eli Lilly

Verdict: a strong Lilly thesis stuck in wait — the entry has never fired

The verdict here is straightforward: a well-supported thesis wrapped around a setup that has never triggered. The strongest point for the idea is Eli Lilly's fundamentals — revenue of $22.97B in the quarter ended June 30, 2026, up 16.0% sequentially, operating cash flow doubling to $10.7B, and a dividend growing 15.3% a year with the quarterly payout stepped up to $1.73. The strongest point against is that the entry rules produced zero trades across 1,234 daily bars over 60 months — including every rally the thesis celebrates — and live conditions remain far away, with LLY at $1,129.76 needing a close above $1,203.1 while 60-day momentum is negative at -31.19. Meanwhile, the freshest ownership filings (period ended June 30, 2026) show net open-market selling of roughly $2.9M at Lilly and $20.2M at Moderna, and the Moderna leg of the pair looks fundamentally broken, with quarterly revenue down 62.7% to $145M and free cash flow of negative $563M. No robust parameter setup was established in the sensitivity review, so the rules must be taken as published. A confirmed close above $1,203.1 alongside positive policy news, or a repeat of insider selling at the next ownership filing deadline, is what would move this off the watch list.

Trade now

## Trade now Nothing to buy yet. LLY closed at $1,129.76, well below the entry condition of a close above the 20-day upper channel at $1,203.1 — the stock needs to rise $73.34, or about 6.5%, before the breakout condition is even in range. The 60-day momentum reading is -31.19 against a required level above zero, so the trend filter also fails. The volatility filter (14-day ATR above 0.5) cannot be checked from the live feed. This is a watch-list setup by design: the rules were run on real daily bars and simply have not fired yet, which says something about market conditions, not about the quality of the idea. Risk framing if the entry does trigger: the stop sits 2.4% below entry with a take-profit 4.9% above entry — an effective reward-to-risk of roughly 2-to-1. Note also that the 50-day moving average sits at $1,187.42, only 5.1% above the current price, so any entry would likely happen above that exit line; the supporting structural stop is the first support level at $1,110.57. "Wait" here means, concretely: no position, and re-check the two live conditions daily — a close above $1,203.1 and 60-day momentum turning positive. When triggered, position sizing is capped at 25% of the portfolio with a fixed 2.44% risk budget per trade. No robust alternative parameter setup was established during the sensitivity review, so the published rules should be taken as-is rather than tweaked.

Lilly's Numbers Actually Back the Breakout Story

The thesis leans on Eli Lilly as the anchor, and on the numbers supplied, that part of the argument holds up. Revenue reached $22.97B in the quarter ended 2026-06-30, up 16.0% from the prior quarter's $19.8B, and the latest full-year snapshot shows 42.5% year-over-year revenue growth — sitting in the 74th percentile of 752 Health Care peers. This is not a story stock; the income statement is expanding in step with the Medicare GLP-1 inclusion narrative cited in the July 1, 2026 Yahoo Finance piece. Profitability is equally strong. Gross margin hit 85.8% in the quarter ended 2026-06-30 (79th percentile among 562 sector peers), and operating cash flow more than doubled quarter-over-quarter to $10.7B from $5.3B. Net income of $7.1B in the latest quarter, against a record full-year $20.6B in 2025, means the catalyst story is being validated by reported results, not just headlines. The shareholder return engine reinforces the case. The dividend has grown at roughly 15.3% annually, with the quarterly payout stepped up from $1.50 to $1.73 across 2026, and the trailing twelve-month payout now stands at $6.69 per share. Share count is also being quietly reduced — 941.4M shares outstanding versus 941.7M a quarter earlier — consistent with a company confident in its cash generation. On evidence tier, it is important to be precise: the rules were evaluated on real daily bars but did not open an entry in any of the three windows tested (60, 24, and 12 months). This is a watch-list setup, not an active signal — the thesis argues the conditions are close, and the fundamental momentum above is what would make…

Scores

• Conviction score breakdown: 46
• Thesis support: 62
• Trade readiness: 35
• Risk quality: 45
• Trigger proximity: 20
• Fundamentals trend: 68

Watch items

• LLY — Close vs 20-day channel upper (Donchian 20)
• LLY — Momentum (60-day)
• LLY — ATR (14-day)
• LLY — Close vs 50-day moving average
• LLY — Close vs first support level
• MRNA — MRNA net margin (Q2 2026, ratio)
• MRNA — MRNA revenue (Q2 2026)
• LLY — LLY insider net open-market value (June 2026 filing)